Sponsor:
Eli Lilly and Company
Code:
NCT04956640
Conditions
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Endometrial Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3537982
Pembrolizumab
Cetuximab
Pemetrexed
Cisplatin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-15. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2025-09-25.